Compare McKesson Corporation (MCK) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Xpeng Inc - ADR — how do they compare? McKesson Corporation trades at $938.84 (market cap $108.46B), while Xpeng Inc - ADR trades at $9.9 (market cap $9.16B). The key difference: McKesson Corporation is far larger — about 11.8× Xpeng Inc - ADR's market cap, and McKesson Corporation pays a 0.4% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Xpeng Inc - ADR for 80 Days on average.
| MCK | XPEV | |
|---|---|---|
Market Cap | $108.46B | $9.16B |
Volume | 712,607 | 5,030,325 |
Sector | Health | Consumer Cyclical |
52-Week High | $995.69 | $28.07 |
52-Week Low | $725.17 | $9.25 |
Typical Hold Time | 74 Days | 80 Days |
Enterprise Value | $115.00B | $11.09B |
Dividend Yield | 0.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $930.25, up 2.19% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
McKesson presents a favorable risk-reward profile with 81% analyst buy ratings and a $956.43 consensus price target offering 2.8% upside. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. The company's strong cash flow generation ($6.1B operating cash flow in 2025) and strategic focus on oncology and specialty distribution support continued growth, though investors should monitor debt levels and competitive pressures in healthcare distribution.
XPeng (XPEV) trades at $9.55, down 0.31% with bearish technical signals despite analyst optimism. The company shows strong revenue growth to $76.72B in 2025 but remains unprofitable with a -$1.14B net loss. Recent vehicle deliveries of 41,256 units in September 2026 and upcoming G9L SUV launch at Paris Motor Show highlight expansion efforts. Cash flow improved significantly with $8.26B from operations in 2025, though negative earnings surprises in Q1 and Q2 2026 raise execution concerns.
XPeng presents a high-risk growth opportunity with 58.8% analyst buy ratings and $17.55 price target suggesting 84% upside. However, persistent losses, competitive EV market pressures, and technical bearishness create significant headwinds. The stock's appeal hinges on successful Physical AI and robotics commercialization alongside sustained delivery growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
